Why the study?
Current imaging for thrombotic cardiovascular diseases relies on structural and functional changes, creating a need for novel non-invasive approaches to enable early, accurate detection and risk stratification.
Key points are not available for this paper at this time.
Design
Review
Molecular imaging using high-sensitivity radiotracers with PET has the potential to improve the non-invasive detection and understanding of thrombosis in cardiovascular diseases.
A key focus of cardiovascular medicine is the detection, treatment, and prevention of disease, with a move towards more personalized and patient-centred treatments. To achieve this goal, novel imaging approaches that allow for early and accurate detection of disease and risk stratification are needed. At present, the diagnosis, monitoring, and prognostication of thrombotic cardiovascular diseases are based on imaging techniques that measure changes in structural anatomy and biological function. Molecular imaging is emerging as a new tool for the non-invasive detection of biological processes, such as thrombosis, that can improve identification of these events above and beyond current imaging modalities. At the forefront of these evolving techniques is the use of high-sensitivity radiotracers in conjunction with positron emission tomography imaging that could revolutionise current diagnostic paradigms by improving our understanding of the role and origin of thrombosis in a range of cardiovascular diseases.
No takes yet. Share an insight, caveat, or question.
Balmforth et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: